Bimatoprost (Lumigan, Latisse)

Bimatoprost (brand names Lumigan for glaucoma; Latisse for cosmetic eyelash growth) is a prostaglandin analog that lowers intraocular pressure in open-angle glaucoma and ocular hypertension. Among the prostaglandin analogs (latanoprost, travoprost, tafluprost), bimatoprost is often among the strongest pressure-lowering options, at the cost of slightly more conjunctival redness and pronounced lash growth - the very effect that became the basis for its sister product, the cosmetic eyelash drug Latisse.

How It Works

Bimatoprost is a synthetic prostamide - structurally a prostaglandin ethanolamide rather than an ester. In the eye it produces FP-receptor-mediated pressure lowering, partly through metabolism to bimatoprost acid and prostamide-sensitive activity. It increases the outflow of aqueous humor through the uveoscleral pathway and trabecular meshwork, lowering intraocular pressure.

The effect:

• Begins within 4 hours of dosing
• Reaches peak at 8-12 hours
• Lasts more than 24 hours, supporting once-daily dosing
• Builds to full effect over 4 weeks

Common Uses

Glaucoma (Lumigan)

• Primary open-angle glaucoma
• Ocular hypertension
• Adjunctive therapy with other classes

Cosmetic Eyelash Growth (Latisse)

• The same molecule (at 0.03% concentration) applied along the upper eyelash line stimulates lash growth
• Approved for this use since 2008
• The mechanism is the same as the side effect seen in patients using bimatoprost for glaucoma

Combinations

• Ganfort - bimatoprost + timolol (regional availability outside the US)

How to Use (for Glaucoma)

• Dosing: One drop in affected eye(s) once daily, in the evening
• Press on the inner corner of the eye for 1-2 minutes after instillation
• Wait 5+ minutes between different eye drops
• Remove contact lenses before use; reinsert after 15 minutes
• More than once-daily dosing does not increase pressure lowering

Side Effects

Local Effects

• Conjunctival hyperemia - somewhat more common than with latanoprost or travoprost, particularly with the 0.03% formulation. Often improves over weeks; the 0.01% formulation reduces the rate.
• Eyelash growth - longer, thicker, darker lashes within 4-6 weeks; the most pronounced of the class
• Iris color darkening - slow change in mixed-color irises; usually permanent
• Periocular and eyelid skin darkening - gradually develops with chronic use; usually fades partially or fully after stopping, but may not always reverse completely
• Periorbital fat atrophy (prostaglandin-associated periorbitopathy) - subtle hollowing of the upper eyelid sulcus; may improve after stopping or switching
• Cystoid macular edema - uncommon; reported in pseudophakic eyes with disrupted posterior capsule
• Reactivation of herpes simplex keratitis in patients with prior history

Systemic Effects

• Minimal - much less than timolol
• Rare reports of mild upper respiratory or muscle aches

Precautions

Prior Herpes Simplex Keratitis

Use cautiously; consider antiviral coverage if recent or recurrent.

Active Uveitis

Avoid in active inflammation; can worsen.

Pseudophakic Eyes with Disrupted Posterior Capsule

Higher cystoid macular edema risk; weigh benefit against risk.

Pregnancy

Discuss use with the prescribing doctor; alternative agents are usually preferred during pregnancy when clinically feasible.

Bimatoprost vs. Other Prostaglandins

Latisse - The Cosmetic Application

Bimatoprost 0.03% is also marketed as Latisse, an FDA-approved treatment for inadequate eyelash growth (hypotrichosis). Applied along the upper lash line nightly with a sterile applicator, it produces longer, thicker, and darker lashes within 8-16 weeks. Effects reverse gradually after stopping.

Important context for glaucoma patients:

• Patients on Lumigan for one eye should not be surprised that lashes on the treated eye grow more than on the untreated side
• The cosmetic use should not be applied to one side only without considering the asymmetry it produces
• Patients using both Latisse and a glaucoma drop should discuss with their doctor

Frequently Asked Questions

Why is the same molecule used for glaucoma and for eyelash growth?

The lash-growth effect was discovered as a side effect of bimatoprost when it was used as a glaucoma drop. Researchers realized this side effect could be exploited as a primary cosmetic application and developed Latisse, which is the same molecule applied along the lash line at 0.03%. The mechanism is the same - prostaglandin stimulation of hair follicle activity.

Will my eye color change?

Iris darkening occurs over 6-12 months in some patients, particularly those with mixed-color irises. The change is gradual and is usually permanent - even after stopping the drop, the new pigment does not reverse. Patients with pure blue or pure brown eyes are less likely to notice a change.

Is bimatoprost more effective than latanoprost?

In direct comparison studies, bimatoprost produces slightly stronger pressure reduction than latanoprost on average, but the difference is small and individual response varies. Bimatoprost has somewhat more conjunctival redness; latanoprost may be better tolerated cosmetically.

What if my eye is red after starting?

Conjunctival hyperemia (red eye) is common at the start of prostaglandin therapy and typically improves over the first weeks. If it remains bothersome, switching to bimatoprost 0.01% (lower concentration) or to latanoprost (less hyperemia in head-to-head studies) is a reasonable adjustment.

Can I just use Latisse for my glaucoma?

No. Latisse is applied along the lash line, while Lumigan is applied as a drop on the eye surface. The dosing and delivery are different and the cosmetic product is not designed to lower intraocular pressure reliably.

What if I miss a dose?

Take it as soon as you remember if it is the same day; otherwise skip and resume the next day. Do not double up. Missing one dose does not produce a major pressure rise; consistent missed doses leave the eye unprotected.